Astragalus polysaccharide suppresses doxorubicin-induced cardiotoxicity by regulating the PI3k/Akt and p38MAPK pathways

Oxidative Medicine and Cellular Longevity

Volumn 2014, Issue , 2014, Pages

  Cao, Yuan ^a,b   Ruan, Yang ^c   Shen, Tao ^b   Huang, Xiuqing ^b   Li, Meng ^a,b   Yu, Weiwei ^b   Zhu, Yuping ^c   Man, Yong ^b   Wang, Shu ^b   Li, Jian ^a,b  

^a Ministry of Education Beijing   (China)

^b BEIJING HOSPITAL   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ASTRAGALUS POLYSACCHARIDES; CARDIOTOXICITY; DOXORUBICIN; P38MAPK; PI3K/AKT;

ANTIOXIDANT; ASTRAGALUS MEMBRANACEUS EXTRACT; ASTRAGALUS POLYSACCHARIDE; CELL DNA; DOXORUBICIN; HERBACEOUS AGENT; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE; POLYSACCHARIDE; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER PATIENT; CARDIOTOXICITY; CELL DAMAGE; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; ECHOCARDIOGRAPHY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME REGULATION; HEART DISEASE; HEART FAILURE; HEART MUSCLE CELL; HEART MUSCLE INJURY; HEART PROTECTION; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOUSE; MOUSE MODEL; NEWBORN; NICK END LABELING; NONHODGKIN LYMPHOMA; NONHUMAN; OXIDATIVE STRESS; RAT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SMALL CELL LUNG CANCER; WESTERN BLOTTING; ANIMAL; ASTRAGALUS (PLANT); C57BL MOUSE; DRUG EFFECTS; ENZYMOLOGY; FEMALE; METABOLISM; MIDDLE AGED; NEOPLASMS; RANDOMIZATION; RETROSPECTIVE STUDY; SPRAGUE DAWLEY RAT;

ANIMALS; ASTRAGALUS PLANT; CARDIOTOXICITY; DOXORUBICIN; FEMALE; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED C57BL; MIDDLE AGED; NEOPLASMS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHATIDYLINOSITOL 3-KINASES; POLYSACCHARIDES; PROTO-ONCOGENE PROTEINS C-AKT; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; RETROSPECTIVE STUDIES;

EID: 84908312828     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2014/674219     Document Type: Article

References (29)

1. Zhu W., Soonpaa M. H., Chen H., Shen W., Payne R. M., Liechty E. A., Caldwell R. L., Shou W., Field L. J., Acute doxorubicin cardiotoxicity is associated with p53-induced inhibition of the mammalian target of rapamycin pathway. Circulation 2009 119 1 99 106 10.1161/CIRCULATIONAHA.108.799700 2-s2.0-59049091824
2. Lipshultz S. E., Alvarez J. A., Scully R. E., Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart 2008 94 4 525 533 10.1136/hrt.2007.136093 2-s2.0-41149115636
3. Ashour A. E., Sayed-Ahmed M. M., Abd-Allah A. R., Korashy H. M., Maayah Z. H., Alkhalidi H., Mubarak M., Alhaider A., Metformin rescues the myocardium from doxorubicin-induced energy starvation and mitochondrial damage in rats. Oxidative Medicine and Cellular Longevity 2012 2012 13 434195 10.1155/2012/434195 2-s2.0-84862301097
4. Zhang S., Liu X., Bawa-Khalfe T., Lu L.-S., Lyu Y. L., Liu L. F., Yeh E. T. H., Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nature Medicine 2012 18 11 1639 1642 10.1038/nm.2919 2-s2.0-84869209094
5. Zhou S., Starkov A., Froberg M. K., Leino R. L., Wallace K. B., Cumulative and irreversible cardiac mitochondrial dysfunction induced by doxorubicin. Cancer Research 2001 61 2 771 777 2-s2.0-0035863469
6. Zhang Y., Shi P., Yao H., Shao Q., Fan X., Metabolite profiling and pharmacokinetics of herbal compounds following oral administration of a cardiovascular multi-herb medicine (Qishen Yiqi Pills) in rat. Current Drug Metabolism 2012 13 5 510 523 10.2174/1389200211209050510 2-s2.0-84861866755
7. Zhu Y.-P., Shen T., Lin Y.-J., Chen B.-D., Ruan Y., Cao Y., Qiao Y., Man Y., Wang S., Li J., Astragalus polysaccharides suppress ICAM-1 and VCAM-1 expression in TNF-treated human vascular endothelial cells by blocking NF- B activation. Acta Pharmacologica Sinica 2013 34 8 1036 1042 10.1038/aps.2013.46 2-s2.0-84882385668
8. Liu M., Qin J., Hao Y., Luo J., Luo T., Wei L., Astragalus polysaccharide suppresses skeletal muscle myostatin expression in diabetes: involvement of ROS-ERK and NF- B pathways. Oxidative Medicine and Cellular Longevity 2013 2013 10 782497 10.1155/2013/782497 2-s2.0-84893867565
9. low DCs in vitro. Journal of Ethnopharmacology 2011 136 3 457 464 10.1016/j.jep.2010.06.041 2-s2.0-79958780240
10. Chaanine A. H., Hajjar R. J., AKT signalling in the failing heart. European Journal of Heart Failure 2011 13 8 825 829 10.1093/eurjhf/hfr080 2-s2.0-79961068540
11. Pacher P., Liaudet L., Bai P., Mabley J. G., Kaminski P. M., Virág L., Deb A., Szabó É., Ungvári Z., Wolin M. S., Groves J. T., Szabó C., Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction. Circulation 2003 107 6 896 904 10.1161/01.CIR.0000048192.52098.DD 2-s2.0-0037448784
12. Zou F., Mao X.-Q., Wang N., Liu J., Ou-Yang J.-P., Astragalus polysaccharides alleviates glucose toxicity and restores glucose homeostasis in diabetic states via activation of AMPK. Acta Pharmacologica Sinica 2009 30 12 1607 1615 10.1038/aps.2009.168 2-s2.0-74949118250
13. Shen T., Aneas I., Sakabe N., Dirschinger R. J., Wang G., Smemo S., Westlund J. M., Cheng H., Dalton N., Gu Y., Boogerd C. J., Cai C.-L., Peterson K., Chen J., Nobrega M. A., Evans S. M., Tbx20 regulates a genetic program essential to adult mouse cardiomyocyte function. Journal of Clinical Investigation 2011 121 12 4640 4654 10.1172/JCI59472 2-s2.0-84055193910
14. Opfermann U. T., Peivandi A. A., Dahm M., Hilgenstock H., Hafner G., Loos A., Oelert H., Postoperative patterns and kinetics of cTnI, cTnT, CK-MB-activity and CK-activity after elective aortic valve replacement. Swiss Medical Weekly 2001 131 37-38 550 555 2-s2.0-0035934664
15. Huang H.-N., Lu P.-J., Lo W.-C., Lin C.-H., Hsiao M., Tseng C.-J., In situ Akt phosphorylation in the nucleus tractus solitarii is involved in central control of blood pressure and heart rate. Circulation 2004 110 16 2476 2483 10.1161/01.CIR.0000145116.75657.2D 2-s2.0-6444220103
16. Li K., Sung R. Y. T., Wei Z. H., Yang M., Nga H. P., Shuk M. L., Wood Y. C., Zhao H., Man Y. T., Tai F. F., Chi K. L., Yuek O. W., Pak C. N., Thrombopoietin protects against in vitro and in vivo cardiotoxicity induced by doxorubicin. Circulation 2006 113 18 2211 2220 10.1161/CIRCULATIONAHA.105.560250 2-s2.0-33646819975
17. Swain S. M., Whaley F. S., Ewer M. S., Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003 97 11 2869 2879
18. Nitiss K. C., Nitiss J. L., Twisting and ironing: doxorubicin cardiotoxicity by mitochondrial DNA damage. Clinical Cancer Research 2014 20 18 4737 4739 10.1158/1078-0432.CCR-14-0821
19. Dudka J., Burdan F., Korga A., Iwan M., Madej-Czerwonka B., Cendrowska-Pinkosz M., Korobowicz-Markiewicz A., Jodlowska-Jedrych B., Matysiak W., Intensification of doxorubicin-related oxidative stress in the heart by hypothyroidism is not related to the expression of cytochrome P450 NADPH-reductase and inducible nitric oxide synthase, as well as activity of xanthine oxidase. Oxidative Medicine and Cellular Longevity 2012 2012 11 139327 10.1155/2012/139327 2-s2.0-84866181143
20. Bezwoda W. R., Dansey R., Seymour L., High-dose 4′-epiadriamycin for treatment of breast cancer refractory to standard dose anthracycline chemotherapy: achievement of second responses. Oncology 1990 47 1 4 8 10.1159/000226776 2-s2.0-0025100987
21. Fisher P. W., Salloum F., Das A., Hyder H., Kukreja R. C., Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity. Circulation 2005 111 13 1601 1610 10.1161/01.CIR.0000160359.49478.C2 2-s2.0-17144405644
22. Chan K. Y.-Y., Xiang P., Zhou L., Li K., Ng P.-C., Wang C.-C., Zhang L., Deng H.-Y., Pong N.-H., Zhao H., Chan W.-Y., Sung R. Y.-T., Thrombopoietin protects against doxorubicin-induced cardiomyopathy, improves cardiac function, and reversely alters specific signalling networks. European Journal of Heart Failure 2011 13 4 366 376 10.1093/eurjhf/hfr001 2-s2.0-79953145585
23. high T cells. PLoS ONE 2011 6 6 e19811 10.1371/journal.pone.0019811 2-s2.0-79958836318
24. Basuray A., French B., Ky B., Vorovich E., Olt C., Sweitzer N. K., Cappola T. P., Fang J. C., Heart failure with recovered ejection fraction: clinical description, biomarkers, and outcomes. Circulation 2014 129 23 2380 2387 10.1161/CIRCULATIONAHA.113.006855 2-s2.0-84899665429
25. Walsh K., Akt signaling and growth of the heart. Circulation 2006 113 17 2032 2034 10.1161/CIRCULATIONAHA.106.615138 2-s2.0-33646458252
26. Chen Y. L., Zhuang X. D., Xu Z. W., Lu L. H., Guo H. L., Wu W. K., Liao X. X., Higenamine combined with [6]-gingerol suppresses doxorubicin-triggered oxidative stress and apoptosis in cardiomyocytes via upregulation of PI3K/Akt pathway. Evidence-based Complementary and Alternative Medicine 2013 2013 14 970490 10.1155/2013/970490 2-s2.0-84879382113
27. Clark A. S., West K., Streicher S., Dennis P. A., Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Molecular Cancer Therapeutics 2002 1 9 707 717 2-s2.0-0036633164
28. Shen T., Zheng M., Cao C., Chen C., Tang J., Zhang W., Cheng H., Chen K.-H., Xiao R.-P., Mitofusin-2 is a major determinant of oxidative stress-mediated heart muscle cell apoptosis. The Journal of Biological Chemistry 2007 282 32 23354 23361 10.1074/jbc.M702657200 2-s2.0-34548170490
29. Guo R., Wu K., Chen J., Mo L., Hua X., Zheng D., Chen P., Chen G., Xu W., Feng J., Exogenous hydrogen sulfide protects against doxorubicin-induced inflammation and cytotoxicity by inhibiting p38MAPK/NF B pathway in H9c2 cardiac cells. Cellular Physiology and Biochemistry 2013 32 6 1668 1680 10.1159/000356602 2-s2.0-84890448089